Continuous-Infusion β-Lactam Antibiotics During Continuous Venovenous Hemofiltration for the Treatment of Resistant Gram-Negative Bacteria

Abstract

Spanish

French

Objective:

To describe the rationale, principles, and dosage calculations for continuous-infusion β-lactam antibiotics to treat multidrug-resistant bacteria in patients undergoing continuous venovenous hemofiltration (CVVH).

Data Sources:

A MEDLINE search (1968–November 2008) of the English-language literature was performed using the terms continuous infusion and Pseudomonas or Acinetobacter, hemofiltration or CVVH or hemodiafiltration or CVVHDF or continuous renal replacement therapy or pharmacokinetics; and terms describing different β-lactam antibiotics.

Study Selection and Data Extraction:

In vitro, in vivo, and human studies were evaluated that used continuous-infusion β-lactam antibiotics to treat Pseudomonas aeruginosa and Acinetobacter baumannii infections. Studies were reviewed that described the pharmacokinetics of β-lactam antibiotics during CVVH as well as other modalities of continuous renal replacement therapy.

Data Synthesis:

Continuous infusion of β-lactam antibiotics, maintaining drug concentrations 4–5 times higher than the minimum inhibitory concentration, is a promising approach for managing infections caused by P. aeruginosa and A. baumannii. Safe yet effective continuous infusion therapy is made difficult by the occurrence of acute renal failure and the need for renal replacement therapy. Case series and pharmacokinetic properties indicate that several β-lactam antimicrobials that have been studied for continuous infusion, such as cefepime, ceftazidime, piperacillin, ticarcillin, clavulanic acid, and tazobactam, are significantly cleared by hemofiltralion. Methodology and formulas are provided that allow practitioners to calculate dosage regimens and reach target drug concentrations for continuous β-lactam antibiotic infusions during CVVH based on a literature review, pharmacokinetic principles, and our experience at the National Institutes of Health Clinical Center.

Conclusions:

Continuous infusion of β-lactam antibiotics may be a useful treatment strategy for multidrug-resistant gram-negative infections in the intensive care unit. Well-established pharmacokinetic and pharmacodynamic principles can be used to safely reach and maintain steady-state target concentrations of β-lactam antibiotics in critical illness complicated by acute renal failure requiring CVVH.

Keywords

Acinetobacter baumannii β-lactam continuous infusion continuous venovenous hemofiltration Pseudomonas aeruginosa

Get full access to this article

View all access options for this article.

References

Talbot

Bradley

Edwards

Jr.

Gilbert

Scheid

Bartlett

. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657–68.

O'neill

. New antibacterial agents for treating infections caused by multi-drug resistant gram-negative bacteria. Expert Opin Investig Drugs 2008;17:297–302.

Nicasio

Kuti

Nicolau

. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy 2008;28:235–49.

Spellberg

Guidos

Gilbert

. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155–64.

Lodise

Lomaestro

Drusano

; Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006;26:1320–32.

DeRyke

Lee

Kuti

Nicolau

. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006;66:1–14.

Piccoli

Larosa

Marchetti

. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion. J Antimicrob Chemother 2003;52:1047–8.

Craig

. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1–12.

Craig

Ebert

. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1991;74:63–70.

10.

Gerber

Feller-Segessenmann

. In-vivo assessment of in-vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother 1985;15(suppl A):201–6.

11.

Gerber

Feller

Brugger

. Time course of the pharmacological response to beta-lactam antibiotics in vitro and in vivo. Eur J Clin Microbiol 1984;3:592–7.

12.

Mouton

Vinks

. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007;13:598–606.

13.

Kasiakou

Sermaides

Michalopoulos

Soteriades

Falagas

. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005;5:581–9.

14.

Bauer

. Applied clinical pharmacokinetics. New York: McGraw-Hill, 2001: 39–41.

15.

Mouton

Vinks

. Is continuous infusion of β-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996;38:5–15.

16.

Mouton

den Hollander

. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38:931–6.

17.

Cappelletty

Kang

Palmer

Rybak

. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother 1995;39:1797–801.

18.

Tessier

Nicolau

Onyeji

Nightingale

. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Chemotherapy 1999;45:284–95.

19.

Alou

Aguilar

Sevillano

. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother 2005;55:209–13.

20.

Kroeger

Hovde

Mitropoulos

Schafer

Rotschafer

. Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2007;51:3431–3.

21.

Xiong

Caillon

Zhou

. Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both. J Antimicrob Chemother 1995;35:697–706.

22.

Robaux

Dube

Caillon

. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. J Antimicrob Chemother 2001;47:617–22.

23.

Navas

Caillon

Gras-Le Guen

. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. J Antimicrob Chemother 2004;54:767–71.

24.

Daenen

de Vries-Hospers

. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime (letter). Lancet 1988;1:937.

25.

Kuzemko

Crawford

. Continuous infusion of ceftazidime in cystic fibrosis (letter). Lancet 1989;2:385.

26.

Vinks

Brimicombe

Heijerman

Bakker

. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997;40:125–33.

27.

Bosso

Bonapace

Flume

White

. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy 1999;19:620–6.

28.

Rappaz

Decosterd

Bille

Pilet

Bélaz

Roulet

. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 2000;159:919–25.

29.

Domenig

Traunmüller

Kozek

. Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection. Transplantation 2001;71:744–5.

30.

Hayes

Jr.

Kanga

Anstead

Kuhn

. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure. Pediatr Pulmonol 2008;43:511–3.

31.

Gorman

Zed

Dhingra

Ronco

. Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia. Ann Pharmacother 2003;37:513–6. DOI 10.1345/aph.1C315

32.

Bohler

Donauer

Keller

. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 1999;72: S24–8.

33.

Bressolle

Kinowski

de la Coussaye

Wynn

Eledjam

Galtier

. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 1994;26:457–71.

34.

Bugge

. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001;45:929–34.

35.

Golper

Wedel

Kaplan

Saad

Donta

Paganini

. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 1985;8:307–12.

36.

Golper

. Drug removal during continuous hemofiltration or hemodialysis. Contrib Nephrol 1991;93:110–6.

37.

Golper

Marx

. Drug dosing adjustments during continuous renal replacement therapies. Kidney Int Suppl 1998;66: S165–8.

38.

Golper

. Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. Contrib Nephrol 2001;132:349–53.

39.

Joy

Matzke

Armstrong

Marx

Zarowitz

. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998;32:362–75. DOI 10.1345/aph.17105

40.

Keller

Böhler

Czock

Zellner

Mertz

. Individualized drug dosage in patients treated with continuous hemofiltration. Kidney Int Suppl 1999;56: S29–31.

41.

Reetze-Bonorden

Böhler

Keller

. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993;24:362–79.

42.

Schetz

Ferdinande

Van den Berghe

Verwaest

Lauwers

. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995;21:612–20.

43.

Schetz

. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care 2007;13:645–51.

44.

Manns

Sigler

Teehan

. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998;32:185–207.

45.

Kellum

Mehta

Angus

Palevsky

Ronco

; ADQI Workgroup. The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002;62:1855–63.

46.

Brunet

Leblanc

Geadah

Parent

Courteau

Cardinal

. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999;34:486–92.

47.

Product information. Unasyn (ampicillin/sulbactam). New York, NY: Pfizer Roerig, September 2003.

48.

McEvoy

Snow

, eds. AHFS: drug information. Bethesda, MD: American Society of Health-System Pharmacists, 2008.

49.

Kucers

Crowe

Grayson

. The use of antibiotics—a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed. Oxford, England: Butterworth-Heinemann, 1997.

50.

Blum

Kohli

Harrison

Schentag

. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1989;33:1470–6.

51.

Foulds

Stankewich

Marshall

. Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother 1983;23:692–9.

52.

Product information. Azactam (aztreonam). Princeton, NJ: Bristol-Myers Squibb Co., January 2007.

53.

Swabb

Sugerman

Platt

Pilkiewicz

Frantz

. Single-dose pharmacokinetics of the monobactam aztreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother 1982;21:944–9.

54.

Mihindu

JCL

Scheid

Bolton

Spyker

Swabb

Bolton

. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Agents Chemother 1983;24:252–61.

55.

O'neil

Smith

Heckelman

. The Merck index. 13th ed. Whitehouse Station, NJ: Merck & Co., Inc., 2001.

56.

Product information. Maxipime (cefepime). Princeton, NJ: Bristol-Myers Squibb Co., January 2007.

57.

Barbhaiya

Knupp

Forgue

Matzke

Guay

DRP

Pittman

. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 1990;48:268–76.

58.

Tam

McKinnon

Akins

Drusano

Rybak

. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 2003;47:1853–61.

59.

Product information. Fortaz (ceftazidime). Research Triangle Park, NC: GlaxoSmithKline, February 2007.

60.

Leroy

Leguy

Borsa

Spencer

Fillastre

Humbert

. Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother 1984;25:638–42.

61.

Product information. Pfizerpen (penicillin G potassium). New York, NY: Pfizer Roerig, December 2005.

62.

Aronoff

Berns

Brier

. Drug prescribing in renal failure. 4th ed. Philadelphia, PA: American College of Physicians, 1999: 51.

63.

Bryan

Stone

. “Comparably massive” penicillin G therapy in renal failure. Ann Intern Med 1975;82:189–95.

64.

Product information. Zosyn (piperacillin/tazobactam). Philadelphia, PA: Wyeth Pharmaceutical Inc., August 2006.

65.

Johnson

Halstenson

Kelloway

. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992;51:32–41.

66.

Product information. Timentin (ticarcillin/clavulanate). Research Triangle Park, NC: GlaxoSmithKline, December 2004.

67.

Jungbluth

Cooper

Doyle

Chudzik

Jusko

. Pharmacokinetics of ticarcillin and clavulanic acid (Timentin) in relation to renal function. Antimicrob Agents Chemother 1986;30:896–900.

68.

Dalet

Amado

Cabrera

Donate

del Rio

. Pharmacokinetics of the combination of ticarcillin with clavulanic acid in renal insufficiency. J Antimicrob Chemother 1986;17(suppl C):57–64.

69.

Sweetman

, ed. Martindale. 33rd ed. London, England: Royal Pharmaceutical Society of Great Britain, 2002.

70.

Kuang

Verbine

Ronco

. Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy. Clin Nephrol 2007;67:267–84.

71.

Malone

Fish

Abraham

Teitelbaum

. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001;45:3148–55.

72.

Isla

Gascón

Maynar

Arzuaga

Toral

Pedraz

. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther 2005;27:599–608.

73.

Isla

Gascón

Maynar

Arzuaga

Sánchez-Izquierdo

Pedraz

. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy 2007;53:194–201.

74.

Bouman

van Kan

Koopmans

Korevaar

Schultz

Vroom

. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 2006;32:2013–9.

75.

Traunmüller

Schenk

Mittermeyer

Thalhammer-Scherrer

Ratheiser

Thalhammer

. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2002;49:129–34.

76.

Matzke

Frye

Joy

Palevsky

. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother 2000;44:1639–44.

77.

Arzuaga

Maynar

Gascón

. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005;45:168–76.

78.

Lindsay

Bawdon

Quigley

. Clearance of ticarcillin-clavulanic acid by continuous venovenous hemofiltration in three critically ill children, two with and one without concomitant extracorporeal membrane oxygenation. Pharmacotherapy 1996;16:458–62.

79.

Rumpf

Rieger

Doht

Ansorg

Scheler

. Drug elimination by hemofiltration. J Dial 1977;1:677–8.

80.

Kraft

Lode

. Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr 1979;57:195–6.

81.

Joos

Schmidli

Keusch

. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Nephrol Dial Transplant 1996;11:1582–5.

82.

Rohde

Werner

Hickstein

Ehmcke

Drewelow

. Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure. Eur J Clin Pharmacol 1997;53:111–5.

83.

Capellier

Cornette

Boillot

. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit Care Med 1998;26:88–91.

84.

Valtonen

Tiula

Takkunen

Backman

Neuvonen

. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001;48:881–5.

85.

van der Werf

Mulder

Zijlstra

Uges

Stegeman

. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997;23:873–7.

86.

Mariat

Venet

Jehl

. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care 2006;10:1–7.

87.

Langgartner

Vasold

Glück

Reng

Kees

. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 2008;34:1091–6.